ClinicalTrials.gg
CompletedNCT01704781IMIDUpdated Mar 8, 2017Results posted

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)

A Phase 1/2 interventional study of Lenalidomide and Lenalidomide placebo in HIV-1 Infection, sponsored by Bionor Immuno AS. Completed at 4 sites in Germany. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-03-08.

Sponsored by Bionor Immuno AS · Phase 1/2, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

During the course of HIV infection the number of CD4 cells decreases, resulting in a reduced immunological response and ultimately immune deficiency. Vacc-4x is a peptide-based HIV immunotherapy and the primary objective is to strengthen the immune system's response to HIV p24. By adding Lenalidomide, an immunomodulatory agent, as a supporting drug, it is anticipated that the effect of Vacc-4x might be enhanced.

Read the detailed description

Human immunodeficiency virus (HIV) infects the CD4 subset of T-cells that are critical for initiating immune responses to infection. The level of CD4 cells in the blood is a marker of a patient's immunological status. The number of CD4 cells decreases in the course of the HIV infection and results in a reduced immunological response and eventually immune deficiency.

Vacc-4x is one of the few peptide-based therapeutic vaccines tested, and consists of four, slightly modified HIV Gag p24 consensus peptides. Vacc-4x was first tested by intradermal injections using GM-CSF as adjuvant. A recent multinational placebo-controlled study found improvement of vaccine-specific T cell immunity and decrease in viral loads (presented at the AIDS vaccine 2011 conference, Bangkok).

Lenalidomide (CC-5013) is a substance in the class of immunomodulatory agents. The lenalidomide mechanism of action includes anti-neoplastic, pro-erythropoietic, and immunomodulatory properties. Lenalidomide inhibits proliferation of certain hematopoietic tumor cells, enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells.

The anti-HIV p24 immune response resulting from Vacc-4x immunization could in combination with ART potentially improve immune reconstitution in patients who have not fully regained a healthy CD4 level (> 600 x106/L). Adding the immunomodulatory agent Lenalidomide (CC-5013) to Vacc-4x immunization could enhance the immune response to Vacc-4x and further strengthen immune reconstitution.

02

Conditions studied

  • HIV-1 Infection

Browse trials for

Keywords

  • CD4
  • Clinical trial
  • Dose escalation assessment lenalidomide
  • Human immunodeficiency virus-1 (HIV-1)
  • HIV
  • Immunomodulatory
  • Infection
  • Lenalidomide
  • Phase I/II
  • Vaccine
  • Vacc-4x
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 36 is below the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Bionor Immuno AS is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men, age ≥ 18 and ≤ 55 years at the time of screening.
  2. Women, age ≥ 50 and ≤ 55 years at the time of screening, who are not of (see Exclusion criteria, point 9). Childbearing status must be documented.
  3. Clinically stable on ART for the last 18 months (changes in therapy are allowed as long as the viral load is stable).
  4. Well controlled with no treatment failure due to ART resistance in the past
  5. Screening plasma viral load (-1 RNA) less than 50 copies/mL for the last six months. If screening value is between 50-500 copies/mL rescreening is allowed. Single blips (up to 500 copies/mL) are allowed.
  6. Screening ≥ 200x10\^6 cells/L and ≤500x10\^6 cells/L. (Rescreening is allowed)
  7. Laboratory test results within these ranges: (ANC) >1.0x10\^9 /L, count >75x10\^9 /L and eGRF () >60 mL/min
  8. Signed
  9. Willingness to adhere to Global Pregnancy Prevention Risk Management Plan Lenalidomide

Exclusion criteria

Exclusion Criteria:

  1. Reported pre-study AIDS-defining illness within the previous year
  2. Malignant disease.
  3. On chronic treatment with therapy.
  4. disorders, present or in the past if there is an increased risk of disease exacerbation.
  5. Unacceptable values of the hematologic and clinical chemistry parameters (including those associated with hemophilia), as judged by the Investigator or the Sponsor (or designee), including creatinine values >1.5x (ULN), and (SGOT), ALT (SGPT), and alkaline phosphatase values >2.5x ULN.
  6. Concurrent chronic active infection such as viral or C or tuberculosis.
  7. Previous thromboembolic events or patient is currently immobilized
  8. Sexually active subjects who do not adhere to Global Pregnancy Prevention Risk Management Plan Lenalidomide
  9. Current participation in other clinical therapeutic studies.
  10. Females of will be excluded from this trial. A female of childbearing potential (FCBP) is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e. has had menses at any time in the preceding 24 consecutive months).
  11. The development of erythema nodosum if characterized by a desquamating rash while previously
  12. Incapability of compliance to the treatment protocol, in the opinion of the Investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Part A: lenalidomide dose escalation

    All patient receive intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide in a dose escalation (3+3) design. Dose level -1: 2.5 mg Lenalidomide (CC-5013) in the event Dose level 1 is non tolerated dose (NTD) Dose level 1(start): 5 mg Lenalidomide (CC-5013) Dose level 2: 10 mg Lenalidomide (CC-5013) Dose level 3: 25 mg Lenalidomide (CC-5013)

    Drug: Lenalidomide · Drug: Vacc-4X · Drug: rhuGM-CSF

  • Experimental
    Part B: lenalidomide

    Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) \& lenalidomide (dose determined in Part A) two days prior to and at the day of immunization.

    Drug: Lenalidomide · Drug: Vacc-4X · Drug: rhuGM-CSF

  • Placebo comparator
    Part B: lenalidomide placebo

    Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) \& lenalidomide placebo two days prior to and at the day of immunization.

    Drug: Lenalidomide placebo · Drug: Vacc-4X · Drug: rhuGM-CSF

Interventions

  • In Part A a dose escalation design is used (2,5; 5; 10; 25 mg). Part B will use the dose confirmed by Part A

    Also known as: Lenalidomide capsule

  • DrugLenalidomide placebo

    Capsules are identical to the active Lenalidomide capsules used.

    Also known as: placebo

  • Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.

    Also known as: Combination of Vacc-10, Vacc-11, Vacc-12 and Vacc-13.

  • Granulocyte macrophage colony stimulating factor as a local adjuvant

    Also known as: Leukine®

06

What researchers measure

Primary outcomes

  1. Part A: To Establish Highest Tolerated Dose of Lenalidomide, Dose-Limiting Toxicity

    Number of participants in each of the three groups that experienced any dose-limiting toxicity.

    Time frame: 31 days

  2. Part A: To Establish Highest Tolerated Dose of Lenalidomide, CD4 Counts Over Time

    Time frame: 31 days

  3. Part B: Change in CD4 Count

    Change in CD4 count from baseline to Week 26.

    Time frame: Week 26

Secondary outcomes

  1. Part B: Change in CD8 Count

    Change in CD8 count from baseline to week 26.

    Time frame: 26 weeks

  2. Part B: Evaluate the Effect on HIV Viral Load

    Results BLQ (\<20 HIV copies/mL) have been replaced with BLQ/2 = 10 HIV copies/mL while 'not detected' results have been replaced with 0 HIV copies/mL.

    Time frame: 26 weeks

  3. Part B: Incidents of Delayed-type Hypersensitivity

    Delayed-type hypersensitivity measured by induration and erythema.

    Time frame: 26 weeks

  4. Part A and B: Safety and Tolerability

    Time frame: Part A: 31 days and Part B: 26 weeks

07

Results

Posted Mar 8, 2017

Participant flow

Participant flow — Overall Study
MilestonePart A: Lenalidomide 5 mgPart A: Lenalidomide 10 mgPart A: Lenalidopmide 25 mgPart B: LenalidomidePart B: Lenalidomide Placebo
Started3361212
Completed3361212
Not completed00000

Outcome measures

PrimaryPart A: To Establish Highest Tolerated Dose of Lenalidomide, Dose-Limiting Toxicity

Number of participants in each of the three groups that experienced any dose-limiting toxicity.

Time frame:
31 days
Reported as:
Count of participants · Participants
Part A: To Establish Highest Tolerated Dose of Lenalidomide, Dose-Limiting Toxicity
ParticipantsPart A: Lenalidomide 5 mgPart A: Lenalidomide 10 mgPart A: Lenalidopmide 25 mg
Part A: To Establish Highest Tolerated Dose of Lenalidomide, Dose-Limiting Toxicity000
PrimaryPart A: To Establish Highest Tolerated Dose of Lenalidomide, CD4 Counts Over Time
Time frame:
31 days
Reported as:
Mean · 10^6 cells/mL
Part A: To Establish Highest Tolerated Dose of Lenalidomide, CD4 Counts Over Time
10^6 cells/mLPart A: Lenalidomide 5 mgPart A: Lenalidomide 10 mgPart A: Lenalidopmide 25 mg
Baseline437.3 ± 38.30436.3 ± 60.05454.2 ± 86.59
Week 1393.0 ± 167.56317.0 ± 18.52342.2 ± 27.13
Week 4442.0 ± 121.77399.3 ± 15.95450.7 ± 147.02
Week 5432.7 ± 242.47449.0 ± 71.04452.3 ± 66.28
PrimaryPart B: Change in CD4 Count

Change in CD4 count from baseline to Week 26.

Time frame:
Week 26
Reported as:
Mean · 10^6 cells/L
Part B: Change in CD4 Count
10^6 cells/LPart B: LenalidomidePart B: Lenalidomide Placebo
ITT90.9 ± 98.7942.2 ± 81.40
PP106.3 ± 101.0049.1 ± 81.58
SecondaryPart B: Change in CD8 Count

Change in CD8 count from baseline to week 26.

Time frame:
26 weeks
Reported as:
Mean · 10^6 cells/L
Part B: Change in CD8 Count
10^6 cells/LPart B: LenalidomidePart B: Lenalidomide Placebo
Baseline734.2 ± 473.14655.3 ± 325.19
Week 1653.8 ± 382.16784.5 ± 372.96
Week 4744.9 ± 485.49794.5 ± 452.91
Week 12823.0 ± 548.84760.3 ± 432.79
Week 13811.2 ± 557.52663.6 ± 393.95
SecondaryPart B: Evaluate the Effect on HIV Viral Load

Results BLQ (\<20 HIV copies/mL) have been replaced with BLQ/2 = 10 HIV copies/mL while 'not detected' results have been replaced with 0 HIV copies/mL.

Time frame:
26 weeks
Reported as:
Mean · Copies/mL
Part B: Evaluate the Effect on HIV Viral Load
Copies/mLPart B: LenalidomidePart B: Lenalidomide Placebo
Baseline0.8 ± 2.892.5 ± 4.52
Week 15.1 ± 9.300.0 ± 0.00
Week 46.4 ± 8.170.9 ± 3.02
Week 125.5 ± 11.294.3 ± 6.90
Week 137.4 ± 19.771.7 ± 3.89
Week 211.7 ± 3.894.2 ± 5.15
Week 263.5 ± 6.992.5 ± 4.52
SecondaryPart B: Incidents of Delayed-type Hypersensitivity

Delayed-type hypersensitivity measured by induration and erythema.

Time frame:
26 weeks
Reported as:
Count of participants · Participants
Part B: Incidents of Delayed-type Hypersensitivity
ParticipantsPart B: LenalidomidePart B: Lenalidomide Placebo
Week 1, Induration00
Week 1, Erythema01
Week 26, Induration52
Week 26, Erythema66
SecondaryPart A and B: Safety and Tolerability
Time frame:
Part A: 31 days and Part B: 26 weeks
Reported as:
Number · participants
Part A and B: Safety and Tolerability
participantsPart A: Lenalidomide 5 mgPart A: Lenalidomide 10 mgPart A: Lenalidopmide 25 mgPart B: LenalidomidePart B: Lenalidomide Placebo
With any TEAE326109
With TESAE00010
With any AE resultiung in withdrawal00000
Deaths00000

Adverse events

Collected over Adverse events were collected from the time of signing informed consent and until last visit; 31 days in Part A and 26 weeks in Part B. In addition, a 5-year survival follow-up period during which telephone contact from site for all subjects who discontinue treatment at any time will be conducted every 4 months for the first two years and every 6 months thereafter for a minimum of 5 years post-inclusion for survival, cause(s) of death, disease progression and post-treatment therapy(ies).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Lenalidomide 5 mg—0/3 (0%)3/3 (100%)
Part A: Lenalidomide 10 mg—0/3 (0%)2/3 (66.7%)
Part A: Lenalidopmide 25 mg—0/6 (0%)6/6 (100%)
Part B: Lenalidomide—1/12 (8.3%)10/12 (83.3%)
Part B: Lenalidomide Placebo—0/12 (0%)9/12 (75%)
Most frequent serious events
Most frequent serious events
EventPart A: Lenalidomide 5 mgPart A: Lenalidomide 10 mgPart A: Lenalidopmide 25 mgPart B: LenalidomidePart B: Lenalidomide Placebo
Abscess left upper armInfections and infestations0/30/30/61/120/12
Most frequent other events
Showing 10 of 58
Most frequent other events
EventPart A: Lenalidomide 5 mgPart A: Lenalidomide 10 mgPart A: Lenalidopmide 25 mgPart B: LenalidomidePart B: Lenalidomide Placebo
Injection site erythemaGeneral disorders2/31/32/64/122/12
Injection site pruritusGeneral disorders2/30/31/63/122/12
FatigueGeneral disorders1/30/31/62/124/12
Injection site swellingGeneral disorders1/31/30/62/120/12
Injection site indurationGeneral disorders1/30/30/61/120/12
Injection site painGeneral disorders1/30/30/61/122/12
Injection site warmthGeneral disorders1/30/30/60/120/12
Tooth infectionInfections and infestations0/31/30/60/121/12
SunisitisInfections and infestations0/31/30/60/120/12
PruritusSkin and subcutaneous tissue disorders0/30/32/63/120/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part A: Lenalidomide 5 mgPart A: Lenalidomide 10 mgPart A: Lenalidopmide 25 mgPart B: LenalidomidePart B: Lenalidomide PlaceboTotal
Mean43.7 ± 4.1635.7 ± 3.0646.2 ± 5.4244.4 ± 7.9741.5 ± 8.0442.9 ± 7.34
Gender
Gender(Participants)Part A: Lenalidomide 5 mgPart A: Lenalidomide 10 mgPart A: Lenalidopmide 25 mgPart B: LenalidomidePart B: Lenalidomide PlaceboTotal
Female000000
Male336121236
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Lenalidomide 5 mgPart A: Lenalidomide 10 mgPart A: Lenalidopmide 25 mgPart B: LenalidomidePart B: Lenalidomide PlaceboTotal
Hispanic or Latino000000
Not Hispanic or Latino336121236
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Lenalidomide 5 mgPart A: Lenalidomide 10 mgPart A: Lenalidopmide 25 mgPart B: LenalidomidePart B: Lenalidomide PlaceboTotal
American Indian or Alaska Native000000
Asian010012
Native Hawaiian or Other Pacific Islander000000
Black or African American010001
White316121133
More than one race000000
Unknown or Not Reported000000
BMI
BMI(kg/m^2)Part A: Lenalidomide 5 mgPart A: Lenalidomide 10 mgPart A: Lenalidopmide 25 mgPart B: LenalidomidePart B: Lenalidomide PlaceboTotal
Mean23.7 ± 2.3227.9 ± 7.6524.4 ± 1.7523.6 ± 3.8523.5 ± 3.4424.1 ± 3.74
08

Study locations

4 sites
  • EIPMED - Gesellschaft fűr epidemiologische und klinische Forschung in der Medizin mbH Rubensstrasse 125
    Berlin, 12157, Germany
  • Charite Campus, Virchow-Klinikum Medizinische Klinik mit Schwerpunkt Infektiologie Station 59 (Suedring 11) Augustenburger Platz 1
    Berlin, 13353, Germany
  • University Medical Center Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Klinik I für Innere Medizin Klinikum Der Universität zu Köln
    Köln, 50937, Germany
09

References and documents

Publications

  • Asjo B, Stavang H, Sorensen B, Baksaas I, Nyhus J, Langeland N. Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy. AIDS Res Hum Retroviruses. 2002 Dec 10;18(18):1357-65. doi: 10.1089/088922202320935438. PubMed 12487807 ↗
  • Kran AM, Sorensen B, Nyhus J, Sommerfelt MA, Baksaas I, Bruun JN, Kvale D. HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). AIDS. 2004 Sep 24;18(14):1875-83. doi: 10.1097/00002030-200409240-00003. PubMed 15353973 ↗
  • Kvale D, Kran AM, Sommerfelt MA, Nyhus J, Baksaas I, Bruun JN, Sorensen B. Divergent in vitro and in vivo correlates of HIV-specific T-cell responses during onset of HIV viraemia. AIDS. 2005 Mar 24;19(6):563-7. doi: 10.1097/01.aids.0000163932.76531.c6. PubMed 15802974 ↗
  • Sommerfelt MA, Nyhus J, Sorensen B. Novel peptide-based HIV-1 immunotherapy. Expert Opin Biol Ther. 2004 Mar;4(3):349-61. doi: 10.1517/14712598.4.3.349. PubMed 15006729 ↗

Individual participant data

Plan to share: No — Participants have not provided informed consent for their anonymized individual data to be made available beyond that described in the patient information sheet.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2012
First posted
Oct 11, 2012
Start
Sep 2012
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Results first posted
Mar 8, 2017
Last update
Mar 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01704781
Lead sponsor
Bionor Immuno AS
Collaborators
Celgene Corporation
Responsible party
Sponsor
First posted
Oct 11, 2012
Start date
Sep 2012
Primary completion
Aug 2014
Completion
Aug 2014
Results posted
Mar 8, 2017
Last update
Mar 8, 2017

Study contacts

Kim Krogsgaard
study director · Bionor Pharma ASA, Kronprinsesse Märthas Plass 1, P.O. Box 1477 Vika, NO-0116 Oslo, Norway

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion